Diffusion Pharmaceuticals Inc, a clinical-stage biotechnology company focused on extending the life expectancy of cancer patients, has announced the validation of European Patent No.: 2 575 487, entitled Oral Formulations of Bipolar Trans Carotenoids.

This patent is directed to oral formulations of bipolar trans carotenoids including trans sodium crocetinate (TSC). Embodiments of the invention include the novel compositions in the form of a tablet, pill or capsule. The claims also include compositions for the treatment of hypoxia caused by many disorders. This European Patent is based on the same patent application that was allowed by the US Patent and Trademark Office (PTO) in January 2018.

This is another important step in building worldwide intellectual property protection for TSC, its composition of matter and many applications in hypoxic conditions, including cancers, such as glioblastoma multiforme, and stroke and cardiovascular disease, said David Kalergis, chief executive officer of Diffusion Pharmaceuticals. TSC or related compounds delivered orally for hypoxia related disorders may be more patient friendly than intravenous administration. As we speak with potential partners outside of the US, this European patent will support the growing value of TSC. More than 40 patents related to TSC have either been allowed or issued in all geographic areas, and we are pleased that the EU, with a pharmaceutical market size comparable to that of the US, has validated our patent, Kalergis added.